It was Oct. 7, 2020, and Matt Gline wasn’t wasting any time. The CEO of Roivant had word that KKR vet Jim Momtazee’s SPAC had priced late the night before, triggering a green light for anyone interested in pursuing a big check for future operations and riding the financial instrument
Roche has axed one-fifth of its pipeline since the third quarter of 2023 as part of a broader portfolio review aimed at boosting the company’s…
A star-studded mix of venture capitalists and scientists, backed by more than a billion dollars, is launching an ambitious biotech that aims to reinvent drug…
Ochre Bio partnering with Germany’s Boehringer Ingelheim on treatments that will harness the organ’s capacity to regenerate
As it waits for its acquisition by AbbVie to finalize, Cerevel reported a Phase 3 win for one of its programs in Parkinson’s disease. Patients…
Her intentions, revealed in a public filing, comes after the once-hot company’s valuation collapsed from a high of $6 billion.
Boehringer Ingelheim put the spotlight on a pipeline ripe with milestones over the next decade during its full-year 2023 earnings call with the press. Driven…
Regeneron, the 35-year-old drugmaker still led by its co-founders, is getting into the venture investing arena. The New York pharma will commit $100 million per…
Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is…
Siduma Therapeutics, a Yale spinout from Arvinas scientific founder Craig Crews, has closed, a spokesperson for the company confirmed to Endpoints News via email Thursday.…
Before Novartis went all in on MorphoSys for $2.9 billion in February, the Swiss pharma giant initially wanted just one key piece from the German…
